Patents Assigned to The Gov. of the USA as represented by Secretary of the Dept. of Health and Human Services
-
Publication number: 20120027792Abstract: The invention relates to nucleic acids (such as DNA immunization plasmids), encoding fusion proteins containing a destabilizing amino acid sequence attached to an amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased by the presence of the destabilizing amino acid sequence. The invention also relates to nucleic acids encoding secreted fusion proteins, such as those containing chemokines or cytokines, and an attached amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased as a result of being attached to the secretory sequence. The invention also relates methods of increasing the immunogenicity of the encoded proteins for use as vaccines or in gene therapy.Type: ApplicationFiled: July 26, 2011Publication date: February 2, 2012Applicant: The Gov of the USA as represented by the Secretary of the Dept. of Health & Human Services N.I.H.Inventors: George N. Pavlakis, Alexander Gragerov, Barbara K. Felber
-
Publication number: 20090269368Abstract: This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using these immunogens also are provided.Type: ApplicationFiled: December 20, 2007Publication date: October 29, 2009Applicant: The Gov. of the USA as Represented by the Secretary of the Dept.of Health and Human ServicesInventor: David J. FitzGerald
-
Publication number: 20070212363Abstract: A (poly)peptide-Fc fusion molecule, such as an scFv-Fc fusion molecule comprising an scFv fragment and an Fc region from an antibody, related nucleic acids, vectors, and host cells, and a method of inhibiting a viral infection in a mammal, which method comprises administering to a mammal in need thereof the fusion molecule, wherein the fusion molecule binds to an epitope of a viral envelope protein that is inaccessible to whole immunoglobulin molecules due to molecular steric hindrance, or a nucleic acid, optionally in the form of a vector, encoding same, wherein the nucleic acid or vector is optionally contained within a host cell.Type: ApplicationFiled: September 29, 2004Publication date: September 13, 2007Applicant: The Gov of USA, as Represented by the Secretary, Dept. of Health and Human ServicesInventors: Dimiter Dimitrov, Mei-Yun Zhang
-
Publication number: 20070093894Abstract: This invention relates to a method for coating a medical device comprising the steps of applying to at least a portion of the surface of the medical device, a bactericidal coating layer, wherein the bactericidal coating layer comprises a bactericidal agent; and applying to at least a portion of the surface of the medical device, a bacteriostatic coating, wherein the bacteriostatic coating layer comprises a bacteriostatic agent wherein the combination of the bactericidal and bacteriostatic agents are in an effective concentration to inhibit growth of microbial organisms relative to an uncoated medical device. The two antimicrobial agents are used to develop a kit comprising these compositions in one container or in separate containers. The kit is used to coat or flush medical devices prior to or after implantation in a mammal.Type: ApplicationFiled: October 25, 2006Publication date: April 26, 2007Applicants: Baylor College of Medicine, Gov. of the USA As Represented by the Secretary of the Dept. of Health and Human ServicesInventor: Rabih Darouiche
-
Publication number: 20060188872Abstract: The invention provides a novel post-transcriptional regulatory element that can function as an RNA nucleo-cytoplasmic transport element. The invention also provides for an attenuated HIV-1 hybrid virus for use as a vaccine and a kit incorporating the hybrid virus. The kit also includes instructional material teaching the use of the vaccine, where the instructional material indicates that the vaccine is used for the prophylaxis or amelioration of HIV-1 infection in a mammal; that the vaccine is to be administered to a mammal in a therapeutically effective amount sufficient to express a viral protein; where the vaccine will not cause clinically significant CD4+ cell depletion; and, the expression of the viral protein elicits an immune response to the attenuated HIV-1 virus. The invention further provides for a method for screening for post-transcriptional RNA nucleo-cytoplasmic transport element (NCTE) binding proteins.Type: ApplicationFiled: May 16, 2005Publication date: August 24, 2006Applicant: The Gov. of the USA as Represented by the Secretary Dept. of Health and Human ServicesInventors: George Pavlakis, Filomena Nappi
-
Publication number: 20050196822Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.Type: ApplicationFiled: April 22, 2005Publication date: September 8, 2005Applicant: The Gov. of the USA as represented by the Secretary of the Dept of Health and Human ServicesInventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
-
Publication number: 20040147026Abstract: A method is disclosed for improving encapsidation of transgene RNA using retroviral packaging and transfer vectors. An HIV-2 transfer vector, which includes the transgene, is introduced into a packaging cell that is also transfected with (or stably expresses) an HIV-2 derived packaging vector or a combination of packaging vectors. The packaging vector has mutations in packaging signal sequences that are both upstream and downstream of the 5′ splice donor site. The upstream mutation can be a functional deletion of a signal sequence located between the 5′ LTR and the 5′ splice donor site, while the downstream mutation can be a functional deletion of a signal sequence located between the 5′ splice donor site and an initiation codon of the gag gene on the HIV-2 genome. It can also be composed of a combination of two or more partial vectors. A transfer vector, which is introduced into the packaging cell line, has a mutation that renders its splice donor site non-functional.Type: ApplicationFiled: December 9, 2003Publication date: July 29, 2004Applicant: The Gov of the USA as represented by the Secretary of the Dept. of Health and Human ServicesInventor: Suresh K. Arya
-
Publication number: 20030054342Abstract: This disclosure relates to CryoArrays, which permit the analysis of samples (such as protein, nucleic acid, virus, or cell samples) in arrays that are prepared at low temperatures. Because CryoArrays are constructed as a block of substantially columnar samples, the block can be sliced to provide a plurality of identical or substantially identical individual arrays. The individual arrays can be used for parallel analysis of the same array feature set, for instance with different probes or under different conditions. Also provided are methods of making CryoArrays, devices for making CryoArrays, and kits.Type: ApplicationFiled: August 30, 2002Publication date: March 20, 2003Applicant: The Gov. of the USA as represented by Secretary of the Dept. of Health and Human ServicesInventors: Robert A. Star, Takehiko Miyaji, Stephen M. Hewitt, Lance A. Liotta